natgillin/translations-raw huggingface dataset:
Hvis De er på natrium - eller saltfattig diæt, skal De tage hensyn hertil.
To be taken into consideration for patients on a controlled sodium diet.
SÅDAN SKAL DE BRUGE VIMPAT
HOW TO USE VIMPAT
Den gives til Dem i en blodåre af en læge eller sygeplejerske.
It will be admin istered into a vein by a health care professional.
Dosering Vimpat skal gives to gange daglig, én gang om morgenen og én gang om aftenen, på omtrent samme tidspunkt hver dag.
Dosage Vimpat must be administered twice a day, once in the morning and once in the evening, at about the same time each day.
122 Sådan får De Vimpat Vimpat gives til Dem som infusion i en blodåre (intravenøst) af en læge eller sygeplejerske.
How Vimpat is given to you Vimpat is administered as an infusion into a vein (intravenously) by a healthcare professional.
Infusionen varer 15- 60 minutter.
It is infused over 15-60 minutes.
Varigheden af behandlingen med Vimpat- infusionsvæske Lægen vil beslutte, i hvor mange dage De skal have infusioner.
122 Duration of the treatment with Vimpat solution for infusion Your doctor will decide for how many days you will receive the infusions.
Der er erfaringer med Vimpat - infusioner to gange daglig i op til 5 dage.
There is experience with twice daily infusions of Vimpat up to 5 days.
Der fås Vimpat- tabletter og - syrup til langtidsbehandling.
For the long term treatment Vimpat tablets and syrup are available.
Hvis De holder op med at bruge Vimpat Hvis lægen beslutter, at De skal stoppe med Vimpatbehandlingen, vil lægen gradvist nedsætte dosis.
If you stop using Vimpat If your doctor decides to stop your treatment with Vimpat, he/she will decrease the dose step by step.
Brug ikke Vimpat efter den udløbsdato, der står på æsken og hætteglasset.
Do not use Vimpat after the expiry date which is stated on the carton and vial.
Hvert hætteglas med Vimpat- infusionsvæske, opløsning, må kun bruges én gang (engangsbrug).
Any unused solution should be discarded.
Al
These measures will help to protect the environment.
123 ubrugt opløsning skal kasseres.
123 6.
1 ml Vimpat- infusionsvæske, opløsning indeholder 10 mg lacosamid.
1 ml Vimpat solution for infusion contains 10 mg lacosamide.
1 hætteglas indeholder 20 ml Vimpat- infusionsvæske, opløsning, hvilket svarer til 200 mg lacosamid
1 vial contains 20 ml Vimpat solution for infusion equivalent to 200 mg lacosamide.
Natriumchlorid, saltsyre, vand til injektionsvæsker.
The other ingredients are: sodium chloride, hydrochloric acid, water for injection.
Vimpats udseende og pakningsstørrelse Vimpat 10 mg/ ml infusionsvæske er en klar, farveløs opløsning.
What Vimpat looks like and contents of the pack Vimpat 10 mg/ml solution for infusion is a clear, colourless solution.
Vimpat infusionsvæske, opløsning fås i æsker á 1 hætteglas indeholdende 20 ml.
Vimpat solution for infusion is available in packages of 1 vial, containing 20 ml.
124 UCB Pharma, S. A.
España UCB Pharma, S.A.
Vimpat- infusionsvæske, opløsning kan gives uden yderligere fortynding eller kan fortyndes med følgende opløsninger:
Vimpat solution for infusion can be administered without further dilution, or may be diluted with the following solutions:
0, 9% natriumchlorid 9 mg/ ml (0, 9%), 5% glucose 50 mg/ ml eller Ringer’ s laktat opløsning.
0.9% sodium chloride 9 mg/ml (0.9%), 5% glucose 50 mg/ml or lactated Ringer’s solution.
Hvert hætteglas med Vimpat- infusionsvæske, opløsning, må kun bruges én gang (engangsbrug).
Each vial of Vimpat solution for infusion must be used only once (single use).
Al ubrugt opløsning skal kasseres (se pkt. 3).
Any unused solution should be discarded (see section 3).
Viracept er et lægemiddel, der indeholder det aktive stof nelfinavir.
Viracept is a medicine containing the active substance nelfinavir.
Det leveres som et oralt pulver (50 mg per gram) og som blå, aflange tabletter (250 mg).
It is available as an oral powder (50 mg per gram) and as blue, oblong tablets (250 mg).
Dette virus forårsager aids (erhvervet immun defekt syndrom).
It is used in combination with other antiviral medicines to treat adults, adolescents and children over three years of age who are infected with human immunodeficiency virus (HIV-1), the virus that causes acquired immune deficiency syndrome (AIDS).
Behandlingen med Viracept bør kun iværksættes af læger med erfaring i behandling af hiv- infektion.
Treatment with Viracept should be initiated by a doctor who has experience in the treatment of HIV infection.
Det orale pulver kan anvendes til patienter, der ikke er i stand til at sluge tabletter.
The oral powder can be used in patients who are unable to swallow capsules.
Den passende mængde pulver afmåles ved brug af den specielle måleske, der medfølger i pakken, og pulveret blandes med mælk eller mælkeerstatning.
The appropriate amount of powder is measured using the special scoops supplied in the pack, and the powder mixed with milk or formula.
Viracept bør anvendes med forsigtighed til patienter med lever - eller nyreproblemer.
Viracept should be used with caution in patients who have problems with their liver or kidneys.
Viracept kurerer ikke hiv- infektion eller aids, men det kan forsinke den beskadigelse af immunsystemet og den udvikling af infektioner og sygdomme, der er forbundet med aids.
Viracept does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Viracept er blevet undersøgt i kombination med andre antiretrovirale lægemidler i to hovedundersøgelser, der omfattede 605 hiv- smittede patienter i alderen tretten år og derover.
Viracept has been studied in combination with other antiviral medicines in two main studies involving 605 patients aged 13 years or more, who were infected with HIV.
I den anden undersøgelse blev Viracept i kombination med zidovudin og lamivudin (andre antiretrovirale lægemidler) sammenlignet med en kombination af zidovudin og lamivudin hos 297 behandlingsnaive patienter (patienter, der ikke tidligere havde taget antiretrovirale lægemidler til behandling af deres hiv- infektion).
In the second study, Viracept, in combination with zidovudine and lamivudine (other antiviral medicines) was compared with the combination of zidovudine and lamivudine in 297 treatment-naïve patients (who had not taken any antiviral medicines to treat HIV infection before).
Virkningen blev hovedsagelig målt på ændringen i hiv- indholdet i blodet (den virale belastning) og ændringen i antallet af CD4- T- celler i blodet (CD4- celletallet).
The main measures of effectiveness were the change in the levels of HIV in the blood (viral load) and the change in the number of CD4 T-cells in the blood (CD4 cell count).
CD4- T- celler er hvide blodlegemer, der er vigtige ved bekæmpelsen af infektioner, men som dræbes af hiv.
CD4 T-cells are white blood cells that are important in helping to fight infections, but which are killed by HIV.
Efter 24 uger havde Viracept mindsket den virale belastning og øget CD4- celletallet mere end sammenligningspræparaterne.
After 24 weeks, Viracept brought about greater reductions in viral loads and increases in CD4 cell counts than the comparator medicines.
I den anden undersøgelse var den virale belastning faldet med mere end 99% hos de patienter, der tog den høje dosis Viracept, sammenlignet med 95% hos de patienter, der tog sammenligningspræparaterne.
In the second study, viral loads had fallen by more than 99% in the patients taking the higher dose of Viracept, compared with 95% in those taking the comparator medicines.
CD4- celletallet steg med henholdsvis 150 og 95 celler/ mm3.
CD4 cell counts increased by 150 and 95 cells/ mm3, respectively.
Den fuldstændige liste over de indberettede bivirkninger ved Viracept fremgår af indlægssedlen.
For the full list of all side effects seen with Viracept, see the Package Leaflet.
Viracept bør ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for nelfinavir eller nogen af indholdsstofferne.
Viracept should not be used in people who may be hypersensitive (allergic) to nelfinavir or any of the other ingredients.
Viracept bør ikke anvendes til patienter, der får et eller flere af følgende lægemidler: • rifampicin (anvendes til behandling af tuberkulose), • perikum (et naturlægemiddel, der anvendes til behandling af depression), • omeprazol (anvendes til at mindske mavesyreniveauet), • lægemidler, der nedbrydes på samme måde som Viracept, og som er skadelige ved et højt indhold i blodet.
Viracept should not be used in patients who are taking any of the following medicines: • rifampicin (used to treat tuberculosis); • St John’ s wort (a herbal preparation used to treat depression); • omeprazole (used to reduce stomach acid levels); • medicines that are broken down in the same way as Viracept and are harmful at high levels in the blood.
Som med anden hiv- medicin kan patienter, der får Viracept, få lipodystrofi (forandringer i kropsfedtets fordeling), osteonekrose (knoglevævsdød) eller immunreaktiveringssyndrom (infektionslignende symptomer, der skyldes, at immunsystemet genvinder sin funktion).
As with other anti-HIV medicines, patients taking Viracept may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Patienter med leverproblemer (herunder hepatitis B eller C- infektion) kan have øget risiko for leverskade, når de får Viracept.
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Viracept.
Hvorfor er Viracept blevet godkendt?
Why has Viracept been approved?
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Viracept opvejer risiciene ved antiretroviral kombinationsbehandling af voksne, unge og børn i alderen tre år eller derover, der er smittet med human immundefekt virus (HIV- 1).
The Committee for Medicinal Products for Human Use (CHMP) decided that Viracept’ s benefits are greater than its risks in antiretroviral combination treatment of HIV-1 infected adults, adolescents and children of three years of age and older.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Viracept.
The Committee recommended that Viracept be given marketing authorisation.
2/ 3 Viracept blev oprindelig godkendt under ’ særlige omstændigheder ’, da der af faglige årsager kun forelå begrænsede oplysninger på godkendelsestidspunktet.
2/ 3 Other information about Viracept:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Viracept til Roche Registration Limited den 22. januar 1998.
The European Commission granted a marketing authorisation valid throughout the European Union for Viracept to Roche Registration Limited on 22 January 1998.
Markedsføringstilladelsen blev fornyet den 22. januar 2003 og den 22. januar 2008.
The marketing authorisation was renewed on 22 January 2003 and on 22 January 2008.
Den fuldstændige EPAR for Viracept findes her.
The full EPAR for Viracept can be found here.
EU- nummer EU/ 1/ 97/ 054/ 001
EU/ 1/ 97/ 054/ 001
Navn Viracept
Viracept
Styrke 50 mg/ g
50 mg/ g
Indgivelsesvej Oral anvendelse
Oral powder
Emballage Flaske (HPDE)
Oral use
Indhold 144 g
bottle (HDPE) 144 g
Paknings- størrelse 1 flaske + 1 g og 5 g polysyren måleske
1 bottle + 1 g and 5 g polypropylene scoop
Flaske (HPDE) Flaske (HPDE)
bottle (HDPE) bottle (HDPE)
VIRACEPT 50 mg/ g oralt pulver.
VIRACEPT 50 mg/ g oral powder.
Hvert gram oralt pulver indeholder nelfinavir mesilat svarende til 50 mg nelfinavir.
Each gram of oral powder contains nelfinavir mesilate corresponding to 50 mg of nelfinavir.
- indeholder saccharosepalmitat:
- Contains sucrose palmitate:
10, 0 mg pr. gram oralt pulver.
10.0 mg per gram of oral powder.
10, 0 mg saccharosepalmitat,
10.0 mg of sucrose palmitate,
hvilket er en ester, svarer teoretisk til maksimalt 5, 9 mg saccharose, når det er fuldt hydrolyseret.
which is an ester, theoretically corresponds to maximally 5.9 mg of sucrose when fully hydrolysed.
- Indeholder aspartam (E951):
- Contains aspartame (E951):
20, 0 mg aspartam pr. gram oralt pulver
20.0 mg of aspartame per gram of oral powder.
- Indeholder kalium:
- Contains potassium:
50, 0 mg dikaliumphosphat svarende til 22, 5 mg kalium pr. gram oralt
50.0 mg of dibasic potassium phosphate corresponding to 22.5 mg of
pulver.
potassium per gram of oral powder.
Hvidt til off- white amorft pulver.
White to off-white amorphous powder.
VIRACEPT er indiceret til antiretroviral kombinationsbehandling af voksne, unge og børn over 3 år, der er smittet med human immundefekt virus (hiv- 1).
VIRACEPT is indicated in antiretroviral combination treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children of 3 years of age and older.
5. 1
See section 5.1.
Behandling med VIRACEPT skal påbegyndes af en læge med erfaring i behandling af hiv- infektion.
Therapy with VIRACEPT should be initiated by a physician experienced in the management of HIV infection.
5. 2).
VIRACEPT should always be ingested with food (see section 5.2).
Patienter over 13 år:
Patients older than 13 years:
VIRACEPT 250 mg tabletter anbefales til voksne og større børn (se produktresumé for VIRACEPT 250 mg tabletter).
VIRACEPT 250 mg tablets are recommended for adults and older children (see Summary of Product Characteristics for VIRACEPT 250 mg tablets).
Den anbefalede dosis af VIRACEPT 50 mg/ g oralt pulver er 1250 mg to gange daglig (BID) eller 750 mg tre gange daglig (TID) til patienter, som ikke kan tage tabletter.
The recommended dose of VIRACEPT 50 mg/ g oral powder is 1250 mg twice a day (BID) or 750 mg three times a day (TID), for patients unable to take tablets.
5. 1).
The efficacy of the BID (twice daily) regimen has been evaluated versus the TID (three times daily) regimen primarily in patients naïve to PIs (see section 5.1)
Den anbefalede initiale dosis til børn er 50- 55 mg/ kg per dosis to gange daglig eller 25- 30 mg/ kg per dosis tre gange daglig.
For children able to take tablets,
Til børn, som kan tage tabletter, kan der gives VIRACEPT tabletter i stedet for oralt pulver (se produktresumé for VIRACEPT tabletter).
2 VIRACEPT tablets may be administered instead of the oral powder (see Summary of Product Characteristics for VIRACEPT tablets).
2 Den anbefalede dosis af VIRACEPT oralt pulver til indgivelse to gange daglig til børn mellem 3 og 13 år ved anvendelse af en kombination af både den hvide 1 grams måleske og den blå 5 grams måleske fremgår af følgende tabel.
The recommended dose of VIRACEPT oral powder to be administered BID to children aged 3 to 13 years, using a combination of both the white 1 gram and the blue 5 gram scoop is shown in the following table.
Legemsvægt
Body Weight of the patient
Blå måleske 5 gram
Blue Scoop 5 gram
Hvid måleske 1 gram
White Scoop 1 gram
7, 5 til 8, 5 kg
7.5 to 8.5 kg 8.5 to 10.5 kg
-
3 -
10 g
8g 10 g
10, 5 til 1 12 til 14 14 til 16 16 til 18 18 til 22
10.5 to 12 kg 12 to 14 kg 14 to 16 kg 16 to 18 kg 18 to 22 kg over 22 kg
2 kg kg kg kg kg
2 2 3 3 4 5
2 2 3 3 4
plus plus plus plus plus
plus 2 plus 4 plus 1 plus 3 plus 1
2 4 1 3 1 -
12 g 14 g 16 g 18 g 21 g
12 g 14 g 16 g 18 g 21 g 25 g
7, 5 til 8, 5 kg 8, 5 til 10, 5 kg
7.5 to 8.5 kg 8.5 to 10.5 kg
10, 5 til 12 kg 1 12 til 14 kg 1 14 til 16 kg 1 16 til 18 kg 1
10.5 to 12 kg 12 to 14 kg 14 to 16 kg 16 to 18 kg 18 to 23 kg over 23 kg
1 2 3 4
1 1 1 1 2 3
6g 7g 8g 9g
plus plus plus plus plus
plus
1 2 3 4 - -
15 g
6g 7g 8g 9g 10 g 15 g
Det orale pulver kan blandes med vand, mælk, modermælkserstatning, soja- modermælkserstatning, sojamælk, kosttilskud eller budding.
The oral powder may be mixed with water, milk, formula, soy formula, soy milk, dietary supplements, or pudding.
Det anbefales at VIRACEPT 50 mg/ g oralt pulver anvendes inden for 6 timer, når det er blandet med disse midler.
It is recommended that VIRACEPT 50 mg/ g oral powder mixed in these media be used within 6 hours.
På grund af smagen anbefales det ikke at blande VIRACEPT oralt pulver med syreholdig føde eller juice (som f. eks. appelsinjuice, æblejuice eller æblemos).
Dosing media not recommended, due to taste, includes any acidic food or juice (e. g., orange juice, apple juice or apple sauce).
Tilsæt ikke vand til flasker med VIRACEPT 50 mg/ g oralt pulver.
Do not add water to bottles of VIRACEPT 50 mg/ g oral powder.
Der findes ingen specifikke data for patienter med nyreinsufficiens, og der kan derfor ikke gives specifikke doseringsanbefalinger.
Renal and hepatic impairment: there are no data specific for patients with renal impairment and therefore specific dosage recommendations cannot be made.
5. 2).
There are not sufficient data from patients with liver impairment and therefore specific dose recommendations cannot be made (see section 5.2).
Der skal udvises forsigtighed ved administration af VIRACEPT til patienter med nedsat nyre - eller leverfunktion.
Caution should be used when administering VIRACEPT to patients with impaired renal or hepatic function.
4. 5].
Co-administration with medicinal products with narrow therapeutic windows and which are substrates of CYP3A4 [e. g., terfenadine, astemizole, cisapride, amiodarone, quinidine, pimozide, triazolam, orally administered midazolam (for caution on parenterally administered midazolam, see section 4.5), ergot derivatives; see section 4.5].
4. 5).
Co-administration with rifampicin (see section 4.5).
4. 5).
John’ s wort (Hypericum perforatum) must not be used while taking nelfinavir due to the risk of decreased plasma concentrations and reduced clinical effects of nelfinavir (see section 4.5).
VIRACEPT bør ikke administreres samtidig med omeprazol på grund af nedsat eksponering af nelfinavir og nelfinavirs aktive metabolit M8.
VIRACEPT should not be co-administered with omeprazole due to a reduction in exposure to nelfinavir and its active metabolite M8.
4. 5.)
This may lead to a loss of virologic response and possible resistance to VIRACEPT (see section 4.5).
Patienterne skal instrueres om at VIRACEPT ikke helbreder en hiv- infektion, at de fortsat kan få infektioner eller andre sygdomme som er relateret til hiv- sygdommen samt at det ikke er vist at VIRACEPT nedsætter risikoen for overførsel af hiv- sygdommen ved seksuel kontakt eller smittet blod.
Patients should be instructed that VIRACEPT is not a cure for HIV infection, that they may continue to develop infections or other illnesses associated with HIV disease, and that VIRACEPT has not been shown to reduce the risk of transmission of HIV disease through sexual contact or blood contamination.
Immun reaktiveringssyndrom:
Immune reactivation syndrome:
Relevante eksempler er cytomegalovirus retinitis, generaliserede og/ eller fokale mycobakterielle infektioner og Pneumocystis carinii pneumoni.
Relevant examples are cytomegalovirus retinitis, generalised and/ or focal mycobacterium infections, and Pneumocystis carinii pneumonia.
Alle inflammatoriske symptomer bør vurderes og behandling bør påbegyndes efter behov.
Any inflammatory symptoms should be evaluated and treatment instituted when necessary.
Sikkerheden og effekten af nelfinavir er ikke efterprøvet hos patienter med betydelige tilgrundliggende leversygdomme.
The safety and efficacy of nelfinavir has not been established in patients with significant underlying liver disorders.
Ved samtidig behandling med antiretroviral behandling for hepatitis B eller C, henvises også til produktresumeerne for disse produkter.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products.
Patienter med allerede kendt leverdysfunktion, inklusive kronisk aktiv hepatitis har en øget frekvens af leverfunktionsabnormaliteter under antiretroviral kombinationsterapi og bør monitoreres i henhold til standard praksis.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Hvis det hos disse patienter kan påvises at leversygdommen forværres, bør det overvejes at afbryde eller stoppe behandlingen.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.
Der bør i mangel på sådanne studier udvises forsigtighed, idet stigninger i nelfinavir niveauer og/ eller stigninger i lever- enzymer kan forekomme.
In the absence of such studies, caution should be exercised, as increases in nelfinavir levels and/ or increases in liver enzymes may occur.
Dog anses ætiologien for at være multifaktoriel (omfattende anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, højere Body Mass Index (BMI)).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/ or long-term exposure to combination antiretroviral therapy (CART).
Det, er usandsynligt at nelfinavi vil fjernes signifikant ved hæmodialyse eller peritoneal dialyse, da nelfinavir i høj grad er bundet til plasmaproteiner.
Since nelfinavir is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodiaylisis or peritoneal dialysis.
4 Kombination med andre lægemidler:
4 Combination with other medicinal products:
4. 3, 4. 5 og 4. 8).
Caution is advised whenever VIRACEPT is co- administered with medicinal products which are inducers or inhibitors and/ or substrates of CYP3A4; such combinations may require dose adjustment (see also sections 4.3, 4.5 and 4.8).
Derfor anbefales samtidig indtagelse af VIRACEPT og simvastatin eller lovastatin ikke, på grund af en øget risiko for myopati inklusiv rhabdomyolyse.
The HMG (hydroxy-3-methyl-glutaryl) -CoA reductase inhibitors simvastatin and lovastatin are highly dependent on CYP3A4 for metabolism, thus concomitant use of VIRACEPT with simvastatin or lovastatin is not recommended due to an increased risk of myopathy including rhabdomyolysis.
Der skal udvises forsigtighed hvis VIRACEPT indtages samtidig med atorvastatin, som i mindre grad metaboliseres af CYP3A4.
Caution must also be exercised if VIRACEPT is used concurrently with atorvastatin, which is metabolised to a lesser extent by CYP3A4.
Der skal udvises særlig forsigtighed, når der ordineres sildenafil til patienter, som får PI, inklusive nelfinavir.
Particular caution should be used when prescribing sildenafil in patients receiving PIs, including nelfinavir.
4. 5).
Co-administration of a PI with sildenafil is expected to substantially increase sildenafil concentration and may result in an increase in sildenafil associated adverse events, including hypotension, visual changes, and priapism.
Potente induktorer af CYP3A (f. eks. phenobarbital og carbamazepin) kan nedsætte plasmakoncentrationerne af nelfinavir.
Potent inducers of CYP3A (e. g., phenobarbital and carbamazepine) may reduce nelfinavir plasma concentrations.
4. 3 og 4. 5).
Physicians should consider using alternatives when a patient is taking VIRACEPT (see sections 4.3 and 4.5).
Absorptionen af nelfinavir kan blive reduceret i situationer, hvor den gastriske pH øges uanset årsagen hertil.
The absorption of nelfinavir may be reduced in situations where the gastric pH is increased irrespective of cause.
4. 3 og 4. 5).
When nelfinavir is co-administered with omeprazole this may lead to a loss of virologic response and therefore concomitant use is contra-indicated (see section 4.3 and 4.5).
Forsigtighed anbefales når nelfinavir administreres samtidig med andre protonpumpehæmmere (se sektion 4. 5).
Caution is recommended when nelfinavir is co-administered with other proton pump inhibitors (see section 4.5).
4. 5).
VIRACEPT may lead to a decreased AUC of phenytoin; therefore phenytoin concentrations should be monitored during concomitant use with VIRACEPT (see section 4.5).
4. 5).
Methadone AUC may be decreased when co-administered with VIRACEPT; therefore upward adjustment of methadone dose may be required during concomitant use with VIRACEPT (see section 4.5).